anti-CD33 CAR-NK cells (PersonGen BioTherapeutics)

anti-CD33 CAR-NK cells is an investigational allogeneic cell therapy developed by PersonGen BioTherapeutics for the treatment of relapsed or refractory CD33-positive acute myeloid leukemia (AML). The therapy utilizes the NK-92 cell line, which is genetically engineered to express a chimeric antigen receptor (CAR) targeting the CD33 antigen, a myeloid differentiation marker broadly expressed on AML blasts. The CAR construct incorporates signaling domains from CD28, CD137 (4-1BB), and CD3 zeta to enhance activation, signaling, and persistence. In clinical evaluations (NCT02944162), the therapy has demonstrated a favorable safety profile with no significant cytokine release syndrome or graft-versus-host disease reported at doses up to 5 billion cells per patient.

Other names

Chimeric CD33 Antigen Receptor-modified NK92 Cells